Topic：Chinese biotechnology

Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.

Goldman Sachs: US proposes limits on investment in Chinese biotechnology, but conventional drug licensing remains open

A US Treasury draft would restrict equity investments, convertible debt and certain joint venture arrangements involving Chinese biotechnology companies. Goldman Sachs believes conventional licensing transactions can still proceed, but structures involving joint funding and shared profits and losses, or attached equity, may fall under the prohibition.

Goldman Sachs · 2026.10.30 02:44

Proposed U.S. COINS rules would tighten biomedical investment restrictions; boundaries for drug out-licensing remain unclear

J.P. Morgan believes the U.S. Treasury’s proposed rules are stricter than it expected, posing greater risks to private financing and equity-linked partnerships in China’s biopharmaceutical industry. The scope of application to standalone drug licensing remains unclear, and the final coverage could still change.

J.P. Morgan · 2026.10.30 02:44